DOCSLIB.ORG

The Importance of Determining Human

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Importance of Determining Human JMB 2009; 28 (2) DOI: 10.2478/v10011-009-0003-1 UDK 577.1 : 61 ISSN 1452-8258 JMB 28: 97–100, 2009 Original paper Originalni nau~ni rad THE IMPORTANCE OF DETERMINING HUMAN PLACENTAL LACTOGEN IN THE THIRD TRIMESTER OF PREGNANCY ZNA^AJ ODRE\IVANJA HUMANOG PLACENTALNOG LAKTOGENA U TRE]EM TRIMESTRU TRUDNO]E Jasmina Durkovi}1, Bojana Mandi}2 1Department of Genetics , Town Hospital, Subotica, Serbia 2Mega Lab, Biochemical Laboratory, Subotica, Serbia Summary: Human placental lactogen (HPL) is a hormone Kratak sadr`aj: Humani placentalni laktogen (HPL) jeste produced by the placenta with a role in the re gu lation of hormon koji izlu~uje placenta i regulator je fetoplacen- fetoplacental growth. In this paper, the results of HPL de- talnog rasta. U radu su prikazani rezultati odre|ivanja HPL- termination in the third trimester of pregnancy are pre- a u tre}em trimestru trudno}e, sa ciljem da se ispita senzi - sented with the aim of testing the sensitivity of this bio - tivnost tog biohemijskog markera za otkrivanje poreme}aja chemical marker for detecting placental dysfunction, fetal funkcije placente, vitaliteta fetusa i rizika za lo{ ishod. vitality and risk of bad outcome. The tests were performed Ispitivanje je obavljeno na uzorku od 370 rizi~nih trudno}a on 370 women with high-risk pregnancy, between the 20th izme|u 20 i 36 nedelje trudno}e. HPL je odre|en ELISA and 36th week of pregnancy. HPL was determined by an metodom, testovima »Bioserv Diagnostics«, a rezultati su ELISA method using Bioserv Diagnostics tests and the o~itani na rideru »STAT–FAX 303+«. Utvr|en je zna~ajno results were read by a STAT-FAX 303+ reader. When com - sni`en nivo biomarkera HPL kod preeklampsije u pore- pared to normal pregnancy, a significant decrease in the |enju sa normalnom trudno}om (p<0,01), dok je kod level of HPL biomarker was identified in preeclampsia dijabetesa serumski nivo HPL zna~ajno vi{i od normalnog (p<0.01), whereas in diabetes the serum level of HPL was (p<0,01). Ustanovljena je zna~ajna pozitivna korelacija significantly higher (p<0.01). A significant positive correla - izme|u nivoa HPL u trudno}i i te`ine novoro|en~eta, tion between the level of HPL during pregnancy and the obima glave i Apgar skora. Rezultati istra`ivanja ukazuju na weight of a newborn child, its head circumference and to da je maternalna koncentracija biomarkera HPL direktno Apgar score was obtained. The results of the research povezana sa vitalitetom placentalnog tkiva, te se HPL u tre- indicate that the maternal concentration of the HPL bio- }em trimestru trudno}e mo`e koristiti kao pokazatelj pla- marker is directly connected to the vitality of placental tis- centalne insuficijencije i vitaliteta fetusa. sue, so that HPL in the third trimester of pregnancy can be used as an indicator of placental insufficiency and fetal Klju~ne re~i: humani placentalni laktogen, placentalna vitality. insuficijencija Keywords: human placental lactogen, placental insuf fi - ciency Introduction centration of which is dependant on fetal and pla- cental physiology (1). The first hormone test in the Biochemical antenatal tests present biomarker observation of fetal vitality was the determination of analyses in maternal serum and urine, the con - estriol in maternal serum and urine, and later Human Placental Lactogen (HPL), which proved more sensitive in the observation of fetoplacental unit Address for correspondence: function, was discovered (2, 3). Prim Dr sci. med. Jasmina Durkovi} Department of Genetics Human placental lactogen (HPL) is a hormone Town Hospital, Subotica, Serbia produced by the placenta and has a role in the Izvorska 3 regulation of fetoplacental growth, so it is also known Tel: 024 555 222 ext. 404, Fax: 024 555 267 Mobile phone: 063 224 324 as the human chorionic somatotropin hormone (4). e-mail: megalabªnadlanu.com HPL is coded by the genes HPL-3 and HPL-4 within 98 Durkovi}, Mandi}: Human placental lactogen in the third trimester of pregnancy the HGH-V gene locus (human growth hormone birth. Correlation between the level of HPL in the variant gene) and stipulates the expression of normal serum of a pregnant woman and the weight of a placental function (5). Thyroid hormone (T3) stimu - newborn child, its head size measurement and Apgar lates the synthesis and release of the HPL hormone, score was obtained. In the statistical calculation t – one of the most important secretion products in the ratio was used (7). syncytiotrophoblast cells. It is determined in the se- rum of a pregnant woman, most often in the third trimester of pregnancy, and is used to indicate pla- Results cental function (6). The HPL was determined in maternal serum Placental insufficiency leads to complications in three times in the third trimester of pregnancy, bet- pregnancy due to reduced nutritive placental function ween the 24th and 36th week, and included two and oxygenation of the fetus leading to dysfunction of groups of women with high-risk pregnancy, 37 with fetal growth and vitality. Certain conditions in a preg- to x e mia and 46 with diabetes. Fifty normal preg- nant woman, such as hypertension, diabetes, kidney nancies represented the control group (Table I and II). insufficiency, can lead to placental dysfunction. Nor- mally, the concentration of the HPL hormone in ma - ternal serum increases as the pregnancy progresses, Discussion whereas in the case of placental insufficiency its level High-risk pregnancies are accompanied by two decreases. A significant decrease of HPL has been problems – the fetal weight, which is either small for identified in threatened abortions, bleeding, placental the gestation age or too high, and prematurity. Both calcification, intrauterine fetal growth halt, intra- problems lead to high perinatal morbidity and uterine fetal death and in pregnancies which re sulted mortality (8–9). A comparison of the HPL biomarker in children born with fetal distress and asphyxia. in high-risk pregnancy and normal pregnancy was In the states of preeclampsia associated with hy- made and it was noticed that the value of the per tension, and the possible risk of toxemia, the de- biomarker in maternal serum in each tested week of ter mination of HPL biomarker can help us monitor the third trimester of pregnancy was significantly placental function and fetal vitality after the 20th week lower in preeclampsia and significantly higher in of pregnancy. A significant increase in the secretion of HPL biomarker has been noticed in the states of hyperplasia of syncytiotrophoblast, diabetes, Rh Table I The values of HPL marker in the serum of a incompatibility, placental trophoblast tumor and pregnant woman with high risk pregnancy and normal molar pregnancy. The aim of the research has been pregnancy. directed towards the study of HPL biomarker in the serum of women with high risk pregnancy and its HPL (mg/L) Preeclampsia Normal Diabetes connection with the pregnancy outcome. average value pregnancy 24–26 weeks 2.07 ± 1.75 4.15 ± 2.55 6.22 ± 3.05 t = 5.714 t = 7.341 Methods 28–30 weeks 3.36 ± 1.74 5.6 ± 2.91 8.96 ± 4.46 The analysis of HPL biomarker was done in the t = 1.985 t = 8.094 Town Hospital in Subotica between 2002 and 2007. The tests were performed on 370 women with high 34–36 weeks 5.15 ± 1.47 8.35 ± 3.35 11.19 ± 4.02 risk pregnancy, between the 20th and 36th week of t = 9.620 t = 1.460 pregnancy. The indications for analyses were the sta tes associated with a risk of preeclampsia, hypertension, 24–26 weeks p<0.01 df = 85 normal pregnancy kidney insufficiency, proteinuria and edema, dia betes, – preeclampsia as well as ultrasonic detection of intrauterine fetal growth halt and a threatened abortion. p<0.01 df = 94 normal pregnancy – diabetes In high risk pregnancies, 46 with diabetes and 37 with preeclampsia, the HPL was checked three 28–30 weeks p=0.025 df = 85 normal pregnancy times in the third trimester of pregnancy. The HPL – preeclampsia marker level in 50 normal pregnancies represented a p<0.01 df = 94 normal pregnancy control group. – diabetes HPL was determined by an ELISA method using 34–36 weeks p<0.01 df = 85 normal pregnancy Bioserv Diagnostics tests and the results were read by – preeclampsia a STAT-FAX 303+ reader. The weight of a newborn child and the Apgar p=0.082 df = 94 normal pregnancy – diabetes score were monitored in the first minute after the JMB 2009; 28 (2) 99 Table II The parameters of a newborn child in high-risk in uteroplacental circulation reduces the oxygenation pregnancy and normal pregnancy. of the intervillous space (14). Parameters Preeclampsia Normal Diabetes In hypoxia the mitotic activity of cytotrophoblast (average value) pregnancy increases leading to its differentiation into syn cytio - trophoblast. The production of human placental Weight (g) 2895 3314 4190 lacto gen is increased in proliferous syncytiotro - t = 13.492 t = 16.197 phoblast which has a diabetogenous effect, and thus explains the regular occurrence of gestational dia- Apgar/1 min 7.15 9.2 8.56 t = 15.348 t = 6.342 betes in high-risk pregnancies (15). In this paper, a significant correlation between Head size 32.9 33.5 34.7 the level of HPL biomarker in the serum of a pregnant measurement (cm) t = 3.385 t = 8.710 woman and the weight of a newborn child in normal pregnancies and pregnancies complicated by diabe - Weight p<0.01 df = 85 normal pregnancy tes and preeclampsia (p<0.01) has been established. – preeclampsia When HPL is low in the maternal serum of pregnant p<0.01 df = 94 normal pregnancy women suffering from preeclampsia, the weight at – diabetes birth is significantly lower, whereas when HPL is hig h - Apgar p<0.01 df = 85 normal pregnancy er in pregnant women suffering from diabetes, the – preeclampsia weight of a newborn child is significantly higher in p<0.01 df = 94 normal pregnancy – diabetes comparison to the weight of the babies born after normal pregnancies.
Load more

Recommended publications
  • Therapeutic Approaches to Preserve Islet Mass in Type 2 Diabetes
    24 Dec 2005 16:24 AR ANRV262-ME57-17.tex XMLPublishSM(2004/02/24) P1: OJO 10.1146/annurev.med.57.110104.115624 Annu. Rev. Med. 2006. 57:265–81 doi: 10.1146/annurev.med.57.110104.115624 Copyright c 2006 by Annual Reviews. All rights reserved THERAPEUTIC APPROACHES TO PRESERVE ISLET MASS IN TYPE 2DIABETES Laurie L. Baggio and Daniel J. Drucker Department of Medicine, Toronto General Hospital, Banting and Best Diabetes Center, University of Toronto, Toronto, Ontario, Canada M5S 2S2; email: [email protected] KeyWords β-cell mass, apoptosis, neogenesis, proliferation ■ Abstract Type 2 diabetes is characterized by hyperglycemia resulting from in- sulin resistance in the setting of inadequate β-cell compensation. Currently available therapeutic agents lower blood glucose through multiple mechanisms but do not directly reverse the decline in β-cell mass. Glucagon-like peptide-1 (GLP-1) receptor agonists, exemplified by Exenatide (exendin-4), not only acutely lower blood glucose but also engage signaling pathways in the islet β-cell that lead to stimulation of β-cell repli- cation and inhibition of β-cell apoptosis. Similarly, glucose-dependent insulinotropic polypeptide (GIP) receptor activation stimulates insulin secretion, enhances β-cell proliferation, and reduces apoptosis. Moreover, potentiation of the endogenous post- prandial levels of GLP-1 and GIP via inhibition of dipeptidyl peptidase-IV (DPP-IV) also expands β-cell mass via related mechanisms. The thiazolidinediones (TZDs) en- hance insulin sensitivity, reduce blood glucose levels, and also preserve β-cell mass, although it remains unclear whether TZDs affect β-cell mass via direct mechanisms. Complementary approaches to regeneration of β-cell mass involve combinations of factors, exemplified by epidermal growth factor and gastrin, which promote islet neo- genesis and ameliorate diabetes in rodent studies.
    [Show full text]
  • Interleukin 6 Inhibits Mouse Placental Lactogen II but Not Mouse Placental Lactogen I Secretion in Vitro (Trophoblast/Pregnancy/Cytokine) M
    Proc. Natl. Acad. Sci. USA Vol. 90, pp. 11905-11909, December 1993 Physiology Interleukin 6 inhibits mouse placental lactogen II but not mouse placental lactogen I secretion in vitro (trophoblast/pregnancy/cytokine) M. YAMAGUCHI*t, L. OGREN*, J. N. SOUTHARD*, H. KURACHI*, A. MIYAKEt, AND F. TALAMANTES*§ *Department of Biology, University of California, Santa Cruz, CA 95064; and tDepartment of Obstetrics and Gynecology, Osaka University Medical School, Osaka, Japan 565 Communicated by George E. Seidel, Jr., September 7, 1993 (receivedfor review June 9, 1993) ABSTRACT The mouse placenta produces several poly- members ofthe PRL-GH gene family. We have used primary peptides belonging to the prolactin-growth hormone gene fam- cultures of placental cells from several days of pregnancy to ily, including mouse placental lactogen (mPL) I and mPL-II. demonstrate that IL-6 regulates the secretion of mPL-II, but The present study was undertaken to determine whether the not mPL-I, and that the sensitivity of mPL-II secretion to secretion of mPL-I and mPL-H is regulated by interleukin 6 IL-6 varies during gestation. (IL-6), which is present in the placenta and has previously been reported to stimulate the secretion ofpituitary members of this gene family. Effects of human and mouse IL-6 on mPL-I and MATERIALS AND METHODS mPL-II secretion were examined in primary cultures of pla- Hormones, Cytokines, and Antisera. mPL-II and recombi- cental cells from days 7, 9, and 12 of pregnancy. IL-6 caused nant mPL-I were purified as described (10, 16). Rabbit a dose-dependent reduction in the mPL-HI concentration in the anti-mPL-I and rabbit anti-mPL-II antisera have been de- medium of cells from days 9 and 12 of pregnancy but did not scribed (11, 16).
    [Show full text]
  • Placental Growth Hormone-Related Proteins and Prolactin-Related Proteins
    Placental Growth Hormone-Related Proteins and Prolactin-Related Proteins The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Haig, D. 2008. Placental growth hormone-related proteins and prolactin-related proteins. Placenta 29: 36-41. Published Version doi:10.1016/j.placenta.2007.09.010 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11148777 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Placental growth hormone-related proteins and prolactin-related proteins. David Haig Department of Organismic and Evolutionary Biology, Harvard University, 26 Oxford Street, Cambridge MA 02138. e-mail: [email protected] phone: 617-496-5125 fax: 617-495-5667 Keywords: GH, PRL, placenta, endometrial glands, placental lactogen The placentas of ruminants and muroid rodents express prolactin (PRL)-related genes whereas the placentas of anthropoid primates express growth hormone (GH)-related genes. The evolution of placental expression is associated with acclerated evolution of the corresponding pituitary hormone and destabilization of conserved endocrine systems. In particular, placental hormones often evolve novel interactions with new receptors. The adaptive functions of some placental hormones may be revealed only under conditions of physiological stress. Introduction Placental hormones are produced by offspring, but act on receptors of mothers. As such, placental hormones and maternal receptors are prime candidates for the expression of parent-offspring conflict [1,2].
    [Show full text]
  • The Endocrine Function of the Placenta: Interactions Between Trophic Peptides and Hormones
    Placenlal Function and Fetal Nutrition, edited by Frederick C. Battaglia, Nestle Nutrition Workshop Series. Vol. 39. Nestec Ltd.. Vevey/Lippincott-Raven Publishers. Philadelphia. © 1997. The Endocrine Function of the Placenta: Interactions Between Trophic Peptides and Hormones Lise Cedard U. 361 INSERM, Maternite Baudelocque, 121 Boulevard de Port-Royal Paris, France The placenta is classically considered to be a source of hormones that play an important role in the establishment and maintenance of pregnancy. Because of its hemochorial structure, the human placenta produces hormones and easily secretes them into the maternal circulation. They include steroid hormones, such as estrogens and progesterone, and protein hormones, the most important of which are the chori- onic gonadotrophins (hCG), discovered in 1927. During the period from 1960 to 1980, the concept of a fetoplacental unit (1) with a complementary role for the fetus in steroid production offered a new approach to steroid metabolism, and since then new proteins and neuropeptides have been discovered (2,3). However, the lack of innervation of placental tissue highlights the importance of understanding neuroen- docrine regulation of placental physiology. Sophisticated culture methods enabling the study of biologic phenomena occurring during transformation of cytotrophoblast cells into a syncytiotrophoblast (4) have been combined with electron microscopy and histochemistry. Possibilities offered by molecular biology, including in situ hybridization and molecular cloning studies,
    [Show full text]
  • Hormonal Regulation of Fetal Growth
    Inrntuterine Growth Reianlaliim, edited by Jacques Senterre. Nestle Nutrition Workshop Scries, Vol. 18. Nestec Ltd.. Vevey/Raven Press. Ltd., New York © 1989. Hormonal Regulation of Fetal Growth Jean Girard Centre de Recherche sur la Nutrition (CNRS), 92190 Meudon-Bellevue, France The regulation of fetal growth is complex and still very poorly understood. It in- volves genetic factors, maternal nutrition and cardiovascular adaptations, placental growth and function, and to a lesser extent fetal factors, including fetal hormones. The influence of genetic, maternal, and placental factors on fetal growth has been reviewed recently (1) and will not be discussed. The purpose of this chapter is to analyze the specific role of endocrine factors in the determination of fetal growth, assuming that the nutritional supply to the placenta and to the fetus remains un- altered. The major endocrine factors involved in postnatal growth are: (a) growth hor- mone (GH) via the secretion of somatomedin; (b) thyroid hormones; (c) cortisol; and (d) sex steroids at puberty (2,3). Insulin is considered to have a merely permis- sive role in postnatal growth (2,3). In recent years, a body of evidence has accumu- lated to indicate that the fetus may be less dependent on pituitary and thyroid hormones for growth than the older organism, and more dependent on insulin and tissue growth factors. Studies on the endocrine regulation of fetal growth have in- volved several major approaches: ablation of fetal endocrine glands; examination of newborns with congenital endocrine deficiencies; treatment of fetuses with hor- mones; measurement of plasma hormone concentrations and tissue receptor levels during normal or abnormal growth; and in vitro studies of hormone effects on fetal tissues.
    [Show full text]
  • A Role for Placental Kisspeptin in Β Cell Adaptation to Pregnancy
    A role for placental kisspeptin in β cell adaptation to pregnancy James E. Bowe, … , Stephanie A. Amiel, Peter M. Jones JCI Insight. 2019;4(20):e124540. https://doi.org/10.1172/jci.insight.124540. Research Article Endocrinology Reproductive biology During pregnancy the maternal pancreatic islets of Langerhans undergo adaptive changes to compensate for gestational insulin resistance. Kisspeptin has been shown to stimulate insulin release, through its receptor, GPR54. The placenta releases high levels of kisspeptin into the maternal circulation, suggesting a role in modulating the islet adaptation to pregnancy. In the present study we show that pharmacological blockade of endogenous kisspeptin in pregnant mice resulted in impaired glucose homeostasis. This glucose intolerance was due to a reduced insulin response to glucose as opposed to any effect on insulin sensitivity. A β cell–specific GPR54-knockdown mouse line was found to exhibit glucose intolerance during pregnancy, with no phenotype observed outside of pregnancy. Furthermore, in pregnant women circulating kisspeptin levels significantly correlated with insulin responses to oral glucose challenge and were significantly lower in women with gestational diabetes (GDM) compared with those without GDM. Thus, kisspeptin represents a placental signal that plays a physiological role in the islet adaptation to pregnancy, maintaining maternal glucose homeostasis by acting through the β cell GPR54 receptor. Our data suggest reduced placental kisspeptin production, with consequent impaired kisspeptin-dependent β cell compensation, may be a factor in the development of GDM in humans. Find the latest version: https://jci.me/124540/pdf RESEARCH ARTICLE A role for placental kisspeptin in β cell adaptation to pregnancy James E.
    [Show full text]
  • Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases
    nutrients Review Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases João V. S. Guerra 1,2,† , Marieli M. G. Dias 1,3,† , Anna J. V. C. Brilhante 3,4, Maiara F. Terra 1,3, Marta García-Arévalo 1,* and Ana Carolina M. Figueira 1,* 1 Brazilian Center for Research in Energy and Materials (CNPEM), Brazilian Biosciences National Laboratory (LNBio), Polo II de Alta Tecnologia—R. Giuseppe Máximo Scolfaro, Campinas 13083-100, Brazil; [email protected] (J.V.S.G.); [email protected] (M.M.G.D.); [email protected] (M.F.T.) 2 Graduate Program in Pharmaceutical Sciences, Faculty Pharmaceutical Sciences, University of Campinas, Campinas 13083-970, Brazil 3 Graduate Program in Functional and Molecular Biology, Institute of Biology, State University of Campinas (Unicamp), Campinas 13083-970, Brazil; [email protected] 4 Brazilian Center for Research in Energy and Materials (CNPEM), Brazilian Biorenewables National Laboratory (LNBR), Polo II de Alta Tecnologia—R. Giuseppe Máximo Scolfaro, Campinas 13083-100, Brazil * Correspondence: [email protected] or [email protected] (M.G.-A.); ana.fi[email protected] (A.C.M.F.) † Both authors contributed equally to this work. Abstract: Throughout the 20th and 21st centuries, the incidence of non-communicable diseases (NCDs), also known as chronic diseases, has been increasing worldwide. Changes in dietary and physical activity patterns, along with genetic conditions, are the main factors that modulate the Citation: Guerra, J.V.S.; Dias, metabolism of individuals, leading to the development of NCDs. Obesity, diabetes, metabolic M.M.G.; Brilhante, A.J.V.C.; Terra, associated fatty liver disease (MAFLD), and cardiovascular diseases (CVDs) are classified in this M.F.; García-Arévalo, M.; Figueira, group of chronic diseases.
    [Show full text]
  • Preoptic Inputs and Mechanisms That Regulate Maternal Responsiveness
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Repository of the Academy's Library Received Date : 14-Jan-2014 Revised Date : 21-Jul-2014 Accepted Date : 22-Jul-2014 Article type : Review Article Preoptic inputs and mechanisms that regulate maternal responsiveness A. Dobolyi1,2, D.R. Grattan3, D. S. Stolzenberg4 1Laboratory of Molecular and Systems Neurobiology, Institute of Biology, NAP-Hungarian Academy of Sciences and Eötvös Loránd University, Budapest, Hungary 2Laboratory of Neuromorphology, Department of Anatomy, Histology and Embryology, Article Semmelweis University, Budapest, Hungary 3Department of Anatomy and Centre for Neuroendocrinology, School of Medical Sciences, University of Otago, Dunedin, New Zealand 4Department of Psychology, University of California, David CA, USA Corresponding Authors: Prof. Arpad Dobolyi, Laboratory of Molecular and Systems Neurobiology, Institute of Biology, Eötvös Loránd University, Pázmány Péter sétány 1C, Budapest 1117, Hungary email: [email protected] Danielle S. Stolzenberg, Department of Psychology, 135 Young Hall, University of California Davis, CA 95616, USA Email: [email protected] Short title: Preoptic mechanisms of maternal responsiveness Key words: maternal motivation, and maternal behaviour, medial preoptic area of hypothalamus, epigenetics, postpartum period This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to Accepted differences between this version and the Version of Record. Please cite this article as doi: 10.1111/jne.12185 This article is protected by copyright. All rights reserved. Abstract The preoptic area is a well-established centre for the control of maternal behaviour.
    [Show full text]
  • Human Placental Lactogen Administration in the Pregnant Rat: Acceleration of Fetal Growth
    003 1-399818812406-0663$02.00/0 PEDIATRIC RESEARCH Vol. 24, No. 6, 1988 Copyright O 1988 International Pediatric Research Foundation, Inc. Printed in U.S.A. Human Placental Lactogen Administration in the Pregnant Rat: Acceleration of Fetal Growth JAMES W. COLLINS, JR., SANDRA L. FINLEY, DANIEL MERRICK, AND EDWARD S. OGATA Departments of Pediatrics, Obstetrics and Gynecology, Northwestern University Medical School and Prentice Women's Hospital of Northwestern Memorial Hospital and Children's Memorial Hospital, Chicago, Illinois 60611 ABSTRACT. To determine whether administration of hu- servations suggest that placental lactogen may also directly stim- man placental lactogen (hPL) to pregnant rats during late ulate fetal growth. Ovine placental lactogen stimulates glycoge- gestation might enhance fetal growth, we implanted os- nesis in hepatocytes of the fetal rat (4) and sheep (5) and motically driven minipumps to provide 75 pg h PL/24 h on aminoisobutyric acid uptake in diaphragmatic muscle of the fetal day 14 of the rat's 21.5-day gestation. This substantially rat (6). It also stimulates ornithine decarboxylase activity in fetal increased maternal and fetal plasma hPL concentrations. rat liver (7) and somatomedin secretion in fetal and adult tissue By day 18, hPL fetuses were significantly heavier and had (8-10). Handwerger (11) has suggested that these and other larger placentas than controls. From this point until term, observations indicate a critical role for placental lactogen in not their rate of growth (1.20 g/24 h) significantly exceeded only indirectly but also directly stimulating normal fetal growth that of controls (0.95 g/24 h).
    [Show full text]
  • Placental Lactogen-I (PL-I) Target Tissues Identified with an Alkaline Phosphatase–PL-I Fusion Protein
    Volume 46(6): 737–743, 1998 The Journal of Histochemistry & Cytochemistry http://www.jhc.org ARTICLE Placental Lactogen-I (PL-I) Target Tissues Identified with an Alkaline Phosphatase–PL-I Fusion Protein Heiner Müller,1 Guoli Dai, and Michael J. Soares Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, Kansas SUMMARY The rat placenta expresses a family of genes related to prolactin (PRL). Target tissues and physiological roles for many members of the PRL family have yet to be deter- mined. In this investigation we evaluated the use of an alkaline phosphatase (AP) tag for monitoring the behavior of a prototypical member of the PRL family, placental lactogen-I (PL-I). A probe was generated consisting of a fusion protein of human placental AP and rat KEY WORDS PL-I (AP–PL-I). The AP–PL-I construct was stably expressed in 293 human fetal kidney cells, as alkaline phosphatase fusion was the unmodified AP vector that served as a control. AP activity was monitored with a protein colorimetric assay in conditioned medium from transfected cells. Immunoreactivity and ovary, corpus luteum prolactin PRL-like biological activities of the AP–PL-I fusion protein were demonstrated by immuno- receptors blotting and the Nb2 lymphoma cell proliferation assay, respectively. AP–PL-I specifically liver, hepatic prolactin bound to tissue sections known to express the PRL receptor, including the ovary, liver, and receptors choroid plexus. Binding of AP–PL-I to tissues was specific and could be competed with ovine Nb2 lymphoma cells PRL. The results indicate that AP is an effective tag for monitoring the behavior of PL-I and placental lactogen-I suggest that this labeling system may also be useful for monitoring the actions of other pregnancy members of the PRL family.
    [Show full text]
  • Hormones Steroids Antibodies
    Fitzgerald Industries International is the premier provider of over 45,000 highly purified Monoclonal and Polyclonal Antibodies, purified Proteins, ELISA Kits and Specialty Research Products. For more than 20 years our customers have known that they can depend on Fitzgerald Industries to supply them with high quality products for research and further manufacture. Hormones and their receptors play a central role in the regulation of gene expression. These soluble receptors, when bound to their corresponding hormone, regulate gene expression through direct interaction with promoter response elements. Fitzgerald Industries offers a wide selection of tools that can be used to investigate the function of hormones and their receptors, and our current brochure encompasses over 800 antibodies and purified hormones and steroids spanning a vast range of targets including steroid hormones such as Glucocorticoids, Estrogens, Androgens; small peptide hormones such as TRH and vasopressin; protein hormones such as insulin and growth hormones; and glycoprotein hormones such as LH, TSH, and FSH. In addition, we offer comprehensive listings in other research areas including Cancer, Cell Biology, Immunology, Infectious Disease, Signal Transduction, Neuroscience, Cytokines & Growth Factors, Cardiac Markers, Protein Modification, Cell Death & Stress, and many more. Visit our website at www.fitzgerald-fii.com to view our complete offerings and full technical data. www.fitzgerald-fii.com/Hormones & Steroids Hormones & Steroids 1 Fitzgerald Industries International
    [Show full text]
  • Apolipoproteins AI, AII, and CI Stimulate Placental Lactogen Release from Human Placental Tissue. a Novel Action of High Density Lipoprotein Apolipoproteins
    Apolipoproteins AI, AII, and CI stimulate placental lactogen release from human placental tissue. A novel action of high density lipoprotein apolipoproteins. S Handwerger, … , J Barrett, I Harman J Clin Invest. 1987;79(2):625-628. https://doi.org/10.1172/JCI112857. Research Article High density lipoproteins (HDL) stimulated a dose-dependent increase in the release of placental lactogen (hPL) from human placental explants. The stimulation was not prevented by delipidation of HDL but was completely blocked by tryptic digestion. Delipidated apolipoproteins (Apo) AI, AII, and CI also stimulated hPL release but other apolipoproteins were without effect. HDL and Apo CI had no effects on the release of luteinizing hormone and follicle-stimulating hormone from rat pituitary cells or the release of prolactin from human decidual cells. Because placental cells have specific HDL receptors and plasma HDL concentrations increase during pregnancy, these results strongly suggest a role for HDL in the regulation of hPL release during pregnancy possibly independent of their usual role in plasma lipid transport. Find the latest version: https://jci.me/112857/pdf Rapid Publication Apolipoproteins Al, All, and Cl Stimulate Placental Lactogen Release from Human Placental Tissue A Novel Action of High Density Lipoprotein Apolipoproteins S. Handwerger, S. Quarfordt, J. Barrett, and 1. Harman Departments of Pediatrics, Physiology, and Medicine, Duke University Medical Center, Durham, North Carolina 27710 Abstract hPL are poorly understood. Because both plasma HDL (7-9) and hPL (4) concentrations increase progressively during preg- High density lipoproteins (HDL) stimulated a dose-dependent nancy, we have examined whether HDL stimulates the release increase in the release of placental lactogen (hPL) from human of hPL from human placental explants.
    [Show full text]